Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA ® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant...
If approved for this investigational new use, KERENDIA ® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA indicated for adults with type 1 diabetes...
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
3G Capital dumped Microsoft stock and piled into semiconductor names. Here's what the move says about AI investing right now, and whether MSFT remains a buy.
KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy outcome...
Regulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2 -mutated...
Primary results from the Phase II ARASEC trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free...
Up to 90% of menstruators experience PMS symptoms 1 , many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol ® ...
Campaign launches with a Walmart community event and food drive in Clovis, CA on May 14 Additional food collection will take place at Luke Bryan Farm Tour stops in Clovis (May 15) and...
KEY FACTS The Phase III REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide) positron...
Perfuse Therapeutics’ investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR) High...